StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Alnylam Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was 52.8%. For fiscal 2025 it was 8.4%, against -12.4% the year before. The highest annual figure on record is 8.4% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20258.4%+20.8
FY2024Dec 31, 2024-12.4%+11.7
FY2023Dec 31, 2023-24.1%+85.0
FY2022Dec 31, 2022-109.0%−8.0
FY2021Dec 31, 2021-101.0%+73.1
FY2020Dec 31, 2020-174.1%+229.1
FY2019Dec 31, 2019-403.2%+613.3
FY2018Dec 31, 2018-1016.6%−470.6
FY2017Dec 31, 2017-545.9%+323.7
FY2016Dec 31, 2016-869.6%−826.1
FY2010Dec 31, 2010-43.5%+3.8
FY2009Dec 31, 2009-47.3%−20.0
FY2008Dec 31, 2008-27.3%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026148.6%+125.2
Q2 FY2026Jun 30, 202612.7%+22.1
Q1 FY2026Mar 31, 202617.6%+20.7
Q4 FY2025Dec 31, 202510.2%+24.3
Q3 FY2025Sep 30, 202523.4%+45.7
Q2 FY2025Jun 30, 2025-9.3%−6.8
Q1 FY2025Mar 31, 2025-3.1%+10.3
Q4 FY2024Dec 31, 2024-14.1%+17.2
Q3 FY2024Sep 30, 2024-22.3%−42.0
Q2 FY2024Jun 30, 2024-2.6%+84.0
Q1 FY2024Mar 31, 2024-13.3%+41.2
Q4 FY2023Dec 31, 2023-31.4%+30.6
Q3 FY2023Sep 30, 202319.7%+173.3
Q2 FY2023Jun 30, 2023-86.6%+36.8
Q1 FY2023Mar 31, 2023-54.5%+58.2
Q4 FY2022Dec 31, 2022-61.9%+38.0
Q3 FY2022Sep 30, 2022-153.6%−44.6
Q2 FY2022Jun 30, 2022-123.4%−37.4
Q1 FY2022Mar 31, 2022-112.7%+0.1
Q4 FY2021Dec 31, 2021-100.0%+48.9
Q3 FY2021Sep 30, 2021-109.0%+92.3
Q2 FY2021Jun 30, 2021-85.9%+86.5
Q1 FY2021Mar 31, 2021-112.8%+70.4
Q4 FY2020Dec 31, 2020-148.9%+236.4
Q3 FY2020Sep 30, 2020-201.3%+96.4
Q2 FY2020Jun 30, 2020-172.4%+318.5
Q1 FY2020Mar 31, 2020-183.2%+363.2
Q4 FY2019Dec 31, 2019-385.3%+620.0
Q3 FY2019Sep 30, 2019-297.6%+11557.5
Q2 FY2019Jun 30, 2019-490.9%+56.0
Q1 FY2019Mar 31, 2019-546.4%+98.5
Q4 FY2018Dec 31, 2018-1005.3%−630.3
Q3 FY2018Sep 30, 2018-11855.1%−11136.0
Q2 FY2018Jun 30, 2018-546.9%+196.4
Q1 FY2018Mar 31, 2018-644.8%−79.0
Q4 FY2017Dec 31, 2017-375.0%–
Q3 FY2017Sep 30, 2017-719.1%–
Q2 FY2017Jun 30, 2017-743.3%–
Q1 FY2017Mar 31, 2017-565.9%–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?